



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 65669

**Title:** Cellular based treatment modalities for unresectable hepatocellular carcinoma

**Reviewer's code:** 05261716

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Associate Chief Physician, Associate Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-03-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-15 04:07

**Reviewer performed review:** 2021-03-16 04:56

**Review time:** 1 Day

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and is unfortunately associated with an overall poor prognosis and high mortality. The authors briefly introduced the currently approved systemic treatment options and present clinical and experimental evidence of HCC immunotherapeutic treatments. Further, the authors provided an up-to-date compilation of ongoing clinical trials investigating T cells, cancer vaccines and oncolytic viruses. The data is comprehensive and interesting. So I would suggest it publish in WJCO if the authors can address the following concerns. 1. Where are the references?



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 65669

**Title:** Cellular based treatment modalities for unresectable hepatocellular carcinoma

**Reviewer's code:** 05172397

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Academic Fellow, Assistant Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-03-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-15 00:23

**Reviewer performed review:** 2021-03-16 16:25

**Review time:** 1 Day and 16 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This paper summaries immunotherapeutic treatments of hepatocellular carcinoma (HCC), but I do not think the authors provides much unique views. I suggest the authors should focus on one or two topics either in basic study or clinical problem and then give much deep thinking.



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 65669

**Title:** Cellular based treatment modalities for unresectable hepatocellular carcinoma

**Reviewer's code:** 02569794

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Thailand

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-03-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-14 08:14

**Reviewer performed review:** 2021-03-23 07:38

**Review time:** 8 Days and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors described nicely about current treatment of HCC with the details of etiology, incidence, disease staging, systemic medications including kinase inhibitors, antibodies and adoptive cell transfer. The manuscript is well written. Major comments: 1. The authors described about current treatment of HCC by the drugs kinase inhibitors and antibodies, which are not brief, as well as adoptive cell therapy. However, the title only reflected cellular based treatment therefore it should be modified to match story of the manuscript as a whole. If the authors wish to briefly discuss about the systemic treatments other than cellular components a few tables of currently used drugs could be given rather giving quite a long discussion on them. 2. For cell therapy, it would be more interesting for a minireview to have a picture/diagram of the cells used for adoptive transfer and the molecular strategies involving T cell receptor and chimeric antigen receptor for examples. 3. More details should be given about the specific types of TILs currently defined such as CD8, Th17, and gamma delta T cells. Minor comments: There might be perhaps typo errors such as 'Alpha-fetoprotein (AFP) is a glycoprotein "compromised" of 591 amino acids....'. Please check thoroughly.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 65669

**Title:** Cellular based treatment modalities for unresectable hepatocellular carcinoma

**Reviewer's code:** 02569794

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Thailand

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-03-12

**Reviewer chosen by:** Chen-Chen Gao

**Reviewer accepted review:** 2021-04-20 00:33

**Reviewer performed review:** 2021-04-20 01:28

**Review time:** 1 Hour

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
<b>Peer-reviewer statements</b>	Peer-Review: [ ] Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: [ ] Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

This reviewer now recommend that this manuscript is acceptable for publication.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 65669

**Title:** Cellular based treatment modalities for unresectable hepatocellular carcinoma

**Reviewer's code:** 05261716

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Associate Chief Physician, Associate Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2021-03-12

**Reviewer chosen by:** Chen-Chen Gao

**Reviewer accepted review:** 2021-04-20 05:39

**Reviewer performed review:** 2021-04-20 05:52

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

I suggested it is published in WJGO.